| Prev Close | 89.22 |
| Day Low/High | 88.61 / 89.71 |
| 52 Wk Low/High | 80.69 / 104.71 |
| Avg Volume | 542.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 51.64M |
| Market Cap | 4.61B |
| EPS | 2.50 |
| P/E Ratio | 37.81 |
| Div & Yield | N.A. (N.A) |
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of Masimo noninvasive and continuous hemoglobin...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on Tuesday, March 13, 2018 at 4:20 p.
Today at the 2018 HIMSS Annual Conference, Masimo (NASDAQ: MASI) announced the release of Replica™, an application for smart phones and tablets that works in conjunction with Masimo Patient SafetyNet™*, a...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 39th Annual Raymond James Institutional Investors Conference at the Marriott Grande Lakes in Orlando on Wednesday, March 7,...
Masimo (NASDAQ: MASI) today announced its financial results for the fourth quarter ended December 30, 2017.
Masimo (NASDAQ: MASI) announced today that NU Hospitals, a leading nephrology care center in India, has standardized on Masimo technologies across the continuum of care.
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Michigan State University evaluated the performance of noninvasive hemodynamic monitoring (NIHM) using Masimo...
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Bülent Ecevit University in Zonguldak, Turkey compared two noninvasive methods of predicting fluid...
Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse CO-Oximeter ®.
Masimo (NASDAQ: MASI) announced today that it will release fourth quarter and full year 2017 financial results for the period ended December 30, 2017, after the market closes on Tuesday, February 27, 2018.
Masimo (NASDAQ: MASI) announced today FDA clearance of Next Generation SedLine ® brain function monitoring.
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the annual meeting of the Society for Technology in Anesthesia (STA) in Miami, Florida.
Masimo (NASDAQ: MASI) announced today FDA clearance for home use of the Rad-97™ Pulse CO-Oximeter ®.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 36th Annual J.
Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ (ORi™) and RPVi™, an improved...
Masimo (NASDAQ: MASI) announced today that Artemis Hospital, one of the leading multi-specialty hospitals in the Delhi-NCR region of India, is adopting Masimo Patient SafetyNet™*, a supplemental remote...
Masimo (NASDAQ:MASI) announced today FDA clearance and U.
In conjunction with World Pneumonia Day on Sunday, November 12, Masimo (NASDAQ: MASI) announced its continuing efforts to help combat the global burden of pneumonia.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Stifel 2017 Healthcare Conference at the Palace Hotel in New York on Tuesday, November 14, 2017 at 9:30 a.
Masimo (NASDAQ: MASI) announced today that The Jeffrey Lee Williams Foundation has distributed 20 Masimo Rad-57 ® Pulse CO-Oximeters ® to EMS departments in York County, South Carolina, with the majority...
Masimo (NASDAQ: MASI) today announced its financial results for the third quarter ended September 30, 2017.
Masimo (NASDAQ: MASI) announced today that it will release financial results for the third quarter ended September 30, 2017, after the market closes on Tuesday, October 31, 2017.
Masimo (NASDAQ: MASI) announced today that the bankruptcy court in San Diego has issued final judgment, holding that Sotera Wireless Employees misappropriated Masimo trade secrets.
Masimo (NASDAQ: MASI) announced today the U.S.
Masimo (NASDAQ: MASI) announced today the full market release of RAS-45, an adhesive adult and pediatric acoustic respiration sensor for rainbow Acoustic Monitoring ® (RAM™).
Masimo (NASDAQ:MASI) announced today FDA 510(k) clearance and full market release of Rad-97™ Pulse CO-Oximeter ®, including configurations with integrated NomoLine™ capnography and noninvasive blood...
Masimo (NASDAQ: MASI) and the Newborn Foundation today announced that the BORN Project, their joint commitment to the United Nations' Every Woman Every Child (EWEC) initiative, has now screened 52,000 newborns across...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 15th Annual Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York on Tuesday, September 12, 2017 at 1:30 p.
